Raymond James Downgrades ARS Pharmaceuticals to Outperform, Lowers Price Target to $17
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsDowngradesPrice Target
Raymond James analyst Ryan Deschner downgrades ARS Pharmaceuticals (NASDAQ:SPRY) from Strong Buy to Outperform and lowers the price target from $28 to $17.
Raymond James analyst Ryan Deschner downgrades ARS Pharmaceuticals (NASDAQ:SPRY) from Strong Buy to Outperform and lowers the price target from $28 to $17.